This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Basal cell carcinoma (BCC)	Kinesin family member 3A (KIF3A); intraflagellar transport 88 homolog (IFT88)	A study in mice and human tissue suggests that antagonizing KIF3A or IFT88 could help treat BCC. KIF3A and IFT88 are involved in the formation of primary cilia, which are cell-surface structures. In mice, selective knockout of Kif3a or Ift88 caused less tumor proliferation than was seen in Kif3a and Ift88 wild-type controls. Next steps include developing antagonists of KIF3A, IFT88 or other factors involved in primary cilium development.	Unpatented; licensing status not applicable	Wong, S. <i>et al. Nat. Med.</i> ; published online Aug. 23, 2009; doi:10.1038/nm.2011 Contact: Jeremy Reiter, University of California, San Francisco, Calif. e-mail: jeremy.reiter@ucsf.edu
SciBX 2(36); doi:10.1038/scibx.2009.1368 Published online Sept. 17, 2009				